Infinity Pharmaceuticals Inc. (Nasdaq:INFI) said it is stopping phase II trials of its investigational drug Saridegib, IPI-926, which was being evaluated for treating bone cancer.
In particular, the drug was targeting was targeting chondrosarcoma, a common type of bone cancer, and myelofibrosis, an incurable condition that affects the bone marrow.
The 12-patient trial’s interim data showed that Saridegib did not perform better than placebo or that the effect observed did not warrant further study.
Earlier this year, the company had already halted phase II trials of Saridegib in pancreatic cancer, after data showed the drug would not meet the primary endpoint of improving patient survival.
Infinity said it will continue to focus on the ongoing development of drug candidates IPI-504 and IPI-145.
IPI-504 is in a phase II trial for non-small cell lung cancer while IPI-145 is under phase I study in patients with advanced liver cancer.
The company anticipates reporting results from the two trials in the second half of 2012.
Infinity Pharmaceuticals stops Phase II trial of bone cancer drug Saridegib
Published: 09:25 18 Jun 2012 EDT